Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

NCT ID: NCT04065490

Last Updated: 2021-02-05

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 96 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-01
• Study Completion Date: 2022-06-01

Brief Summary

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.

Detailed Description

This study is a double-masked, sham-controlled, parallel design prospective, multi-site study on the use of photobiomodulation (PBM) as a treatment for visual impairment in subjects with dry AMD. Subjects will receive repeated sham or PBM treatments at several time-points throughout the 2-year study.

Conditions

Dry Age-related Macular Degeneration

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

PBM Treatment

The Valeda™ Light Delivery System

Group Type: EXPERIMENTAL

Valeda PBM treatment

Intervention Type: DEVICE

The Valeda Light Delivery System

Sham Treatment

The Valeda™ Light Delivery System non-effective treatment

Group Type: SHAM_COMPARATOR

Valeda Sham treatment

Intervention Type: DEVICE

The sham mode of the Valeda Light Delivery System.

Interventions

Valeda PBM treatment

The Valeda Light Delivery System

Intervention Type: DEVICE

Valeda Sham treatment

The sham mode of the Valeda Light Delivery System.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male or female at least 50 years of age at Screening visit

2. ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to 20/32). *If the subject meets this criterion at the Screening Visit, but the Baseline BCVA letter score is between 48 and 77, the subject may be entered in the study.

3. Diagnosis of dry AMD as defined by the presence of the following:

Drusen that are intermediate in size or larger (63 μm or larger in diameter) with at least a few (3) being regular drusen and not pseudodrusen and/or geographic atrophy (GA) visible on two of the following: color fundus images, OCT and/or FAF, to be confirmed by the reading center

4. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study

5. Informed of the nature of this study and has provided written, informed consent in accordance with institutional, local and national regulatory guidelines

Exclusion Criteria

1. Current or history of neovascular maculopathy that includes any of the following (to be confirmed by the reading center):

1. Choroidal neovascularization (CNV) defined as pathologic angiogenesis originating from the choroidal vasculature that extends through a defect in Bruch's membrane

2. Serous and/or hemorrhagic detachment of the neurosensory retina or retinal pigment epithelial (RPE)

3. Retinal hard exudates (a secondary phenomenon resulting from chronic intravascular leakage)

4. Subretinal and sub-RPE fibrovascular proliferation

5. Disciform scar (subretinal fibrosis)

2. Presence of center involving GA within the central ETDRS 1 mm diameter at Screening, to be confirmed by the reading center

3. Media opacities, including cataracts, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the next 24 months.

4. Posterior capsule opacification, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require surgery in the study eye in the next 24 months.

5. Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3 months prior to Screening

6. Ocular disorder or disease that partially or completely obstructs the pupil (e.g. posterior synechia in uveitis)

7. Visually significant disease in any ocular structure apart from dry AMD (e.g. diabetic macular edema, glaucoma (using >2 eye drop medications, uncontrolled IOP and/or central/paracentral visual field loss), glaucoma surgery, active uveitis, active vitreous disease, intraocular tumor, retinal vascular diseases)

8. Ocular disorder or disease other than dry AMD that could cause drusen (glomerulonephritis Type 2, Autosomal dominant drusen), GA (North Carolina dystrophy) or mitochondrial diseases (parafoveal petaloid GA, Stargardt disease)

9. Presence or history of disease or condition affecting functional vision without obvious structural abnormalities (e.g. amblyopia, stroke, nystagmus)

10. Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study

11. Presence of or history of malignancy within the past 5 years other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ

12. Is non-ambulatory

13. Presence or history of known light sensitivity to yellow light, red light, or near infrared radiation (NIR), or if they have a history of light activated CNS disorders (e.g. epilepsy, migraine)

14. Use of any photosensitizing agent (e.g. topicals, injectables, oral) within 30 days of treatment without consulting subject's physician

15. History of drug, alcohol or substance abuse within 3 months prior to Screening

16. Has received an investigational drug or treatment with an investigational device within 3 months prior to Screening

17. If on any anti-oxidant or vitamin Age-Related Eye Disease Study (AREDS) supplement for dry AMD, has not been stabilized for a minimum of 1 month prior to Screening. Subjects are considered to be stable if they are taking the AREDS supplements consistently as prescribed by their treating doctor.

18. Has received Low Vision Rehab/Therapy within 30 days prior to Screening or intends to receive during the study

19. Has an open sore(s) that may come in contact with the Valeda System, has periorbital skin erythema or is prone to such conditions with exposure to light.

20. In the opinion of the Investigator, is unlikely to comply with the study protocol

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LumiThera, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Retina Vitreous Associates Medical Group

Beverly Hills, California, United States

Stanford University

Palo Alto, California, United States

Florida Eye Clinic

Altamonte Springs, Florida, United States

Cumberland Valley Retina Consultants

Hagerstown, Maryland, United States

Mid Atlantic Retina

Cherry Hill, New Jersey, United States

New York Ear and Eye Infirmary

New York, New York, United States

Duke Eye Center

Durham, North Carolina, United States

Cumberland Valley Retina Consultants

Chambersburg, Pennsylvania, United States

Gulf Coast Eye Institute

McAllen, Texas, United States

Retina Consultants of Houston

The Woodlands, Texas, United States

Retina Center Northwest

Silverdale, Washington, United States

Countries

United States

Other Identifiers

CSP005

Identifier Type: -

Identifier Source: org_study_id